Open Primary Retroperitoneal Lymph Node Dissection Shows Acceptable Morbidity
By Lori Solomon HealthDay Reporter
TUESDAY, Nov. 5, 2024 -- Open primary retroperitoneal lymph node dissection (RPLND) has an acceptable morbidity profile in men with testicular cancer, according to a study published online Sept. 3 in BJU International.
Jacob D. McFadden, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues characterized current perioperative outcomes and short-term complication rates for open primary retroperitoneal lymph node dissection. The analysis included 165 patients undergoing surgery from 2018 to 2021.
The researchers found that patients most often had clinical stage IIA (39 percent) or IIB testicular cancer (36 percent). No transfusions were required, and median estimated blood loss was 150 mL. Compared with normal recovery, higher body mass index (median, 28.6 kg/m2) was seen in patients who sustained any complication. Three days was the median length of hospital stay. There was a low overall complication rate (8.48 percent), with two major postoperative complications, including one case of chylous ascites (0.6 percent). No deaths were seen in the 30-day period.
"While contemporary reports on the robotic approach to primary RPLND indicate feasibility and potential benefits with respect to blood loss and hospital stay, our report suggests that the open approach remains the ‘gold standard’ by most peri-operative metrics," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Helping Others Linked to Higher Level of Cognitive Function
THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...
Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes
THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.